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Abstract
Background: Coronary artery calcification (CAC) is highly prevalent among dialysis patients and is associated with
increased cardiovascular and all cause mortality. Magnesium (Mg) inhibits vascular calcification in animal and in-vitro
studies but whether the same effect occurs in humans is uncertain.
Methods: A single centre cross-sectional study of 80 prevalent peritoneal dialysis (PD) patients; on PD only for a
minimum of 3 months. A radiologist blinded to patient status calculated their abdominal aortic calcification (AAC)
scores on lateral lumbar spine radiographs, a validated surrogate for CAC.
Results: Eighty patients provided informed consent and underwent lumbar spine radiography. The mean serum Mg was
0.8 mmol/L (standard deviation 0.2) and mean AAC score 8.9 (minimum 0, maximum 24). A higher serum Mg level was
associated with a lower AAC score (R2 = 0.06, unstandardized coefficient [B] = −7.81, p = 0.03), and remained after
adjustment for age, serum phosphate, serum parathyroid hormone, low-density lipoprotein cholesterol, smoking history,
and diabetes (model adjusted R2 = 0.36, serum Mg and AAC score B = −11.44, p = 0.00). This translates to a 0.1 mmol/L
increase in serum Mg being independently associated with a 1.1-point decrease in AAC score.
Conclusions: Our findings suggest that Mg may inhibit vascular calcification. If this association is replicated across larger
studies with serial Mg and vascular calcification measurements, interventions that increase serum Mg and their effect on
vascular calcification warrant further investigation in the PD population.
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Background
The mortality rate of patients on dialysis is in excess of
20% per year, with approximately one half of deaths attrib-
utable to cardiovascular disease [1, 2]. Dialysis patients
have a high prevalence of traditional cardiac risk factors
and experience further risk due to abnormal mineral me-
tabolism [1]. Studies in prevalent hemodialysis (HD) pa-
tients have found that 90% of such patients have coronary
artery calcification (CAC), which is associated with in-
creased all cause and cardiovascular mortality [2–4]. Hy-
percalcemia, hyperphosphatemia, and hyperparathyroidism
have received the most attention; several studies have dem-
onstrated their association with accelerated vascular calcifi-
cation [5]. However, there has been comparatively little
exploration of the association of serum magnesium (Mg)
with vascular calcification. Both in-vitro and animal studies
have found that the addition of Mg to vascular smooth
muscle cells inhibits the increase in mineralization associ-
ated with an osteoblastic phenotype, increases the expres-
sion of anti-calcification proteins, and down regulates
pathways necessary for the development of vascular calcifi-
cation [6–12]. The transient receptor potential melastin
(TRPM)7 cation channel as well as the Wnt/β-catenin
pathway are proposed as being essential to Mg regulating
vascular calcification [7, 11]. Small observational studies
and pilot studies administering Mg containing phosphate
binders in dialysis populations have found a significant
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association between lower serum Mg levels and the pro-
gression of CAC, peripheral arterial calcification, mitral an-
nular calcification, and atherosclerosis of the common
carotid artery [13–19]. A recent study demonstrated that a
higher serum Mg significantly decreased the mortality risk
associated with hyperphosphatemia in HD patients [20] As
well, a lower serum Mg level has been found to be associ-
ated with increased mortality in both HD and PD patients
[21–27]. These cumulative results suggest a possible asso-
ciation between hypomagnesemia and CAC. The majority
of studies have used poorly validated surrogates for CAC,
[3, 28] and only one study included PD patients, [16] who
are at highest risk for hypomagnesemia due to the low Mg
concentration of commonly used PD solutions [29, 30]. To
better characterize the relationship between serum Mg and
CAC in PD patients, we performed a cross sectional study
using the degree of abdominal aortic calcification (AAC)
seen on a lateral lumbar spine radiograph, a validated and
inexpensive surrogate for CAC [28, 31].
Methods
Dialysis prescription
Patients in the Ottawa Hospital Home Dialysis Program
in Ottawa, Ontario, Canada were recruited from 2012 to
2014. These individuals are assessed routinely in a
multi-disciplinary clinic every six weeks and recruitment
was performed at a regular clinic visit. Included patients
had to be on PD for a minimum of three months and
had to be capable of providing informed consent. Pa-
tients on hybrid therapy (combined HD and PD) were
excluded. Because the study was of cross-sectional de-
sign, all variables were measured once upon patient en-
rollment. Our Home Dialysis Program exclusively used
PD solutions provided by Baxter Healthcare Corporation
(Deerfield, Illinois) during the study period. Solutions
used included Dianeal, Extraneal, and rarely Physioneal.
Information on these solutions and their composition is
available at: http://www.baxter.com/healthcare_profes-
sionals/products/index.html#Renal. Patients are offered
a choice between continuous ambulatory peritoneal dia-
lysis and continuous cyclic peritoneal dialysis. The dialy-
sis programs are adjusted to deliver a minimum weekly
Kt/V urea of 1.7 as per Canadian Society of Nephrology
guidelines [32].
Biochemical assays
At the time of enrolment, a patient’s serum calcium (Ca),
phosphate (PO4), parathyroid hormone (iPTH), albumin,
Mg and a non-fasting cholesterol profile were measured.
All samples were analyzed in the Hospital Laboratory in
accordance with the Hospital Laboratory Guidelines.
Serum Ca and PO4 were analyzed with the Siemens Vista
1500 analyzer (Munich, Germany) (coefficient of variation
(CV) for Ca 2.63% at 1.42 mmol/L and 2.1% at 2.5 mmol/
L; CV for PO4 3.4% at 0.6 mmol/L and 2.4% at 1.3 mmol/
L). iPTH was analyzed using the Beckman Coulter Im-
munoassay (Brea, California) (CV 6.9% at 2.6 pmol/L,
6.9% at 19.9 pmol/L and 5.8% at 59.3 pmol/L). Serum al-
bumin was analyzed with the Dimension Vista (Siemens,
Munich, Germany) system using an adaptation of the bro-
mocresol purple dye binding method (CV 2.5% at 3.2 g/
dL). Serum Mg was analyzed with the Dimension Vista
system using a modification of the methylthymol blue
complexometric procedure (CV 3% at 0.78 mmol/L and
2% at 1.93 mmol/L). Serum total cholesterol, triglycerides
and high-density lipoprotein cholesterol (HDL) were mea-
sured using the Dimension Vista system (CHOL, TRIG
and HDLC methods respectively). Low-density lipoprotein
cholesterol (LDL) was calculated using Friedewald’s for-
mula. Residual renal function (RRF) was calculated from a
24-h urine collection. Urine creatinine and urine urea
were measured; the average of the creatinine clearance
and urea clearance was taken to calculate the estimated
glomerular filtration rate (eGFR) in mL/min.
Vascular calcification
The AAC score was calculated using a lateral lumbar
spine radiograph as described by Kauppila et al. from their
assessment of 617 Framingham heart study participants
[31]. The extent of the calcification of the anterior and
posterior aortic wall was graded at each vertebral level
from L1 to L4 on a 0–3 scale, yielding three different com-
posite scores. Of these, the antero-posterior severity score,
which ranges from 0 to 24 and has the highest inter-rater
correlation (intra-class correlation (ICC) 0.93–0.96), was
used in our study [31]. This method of determining ab-
dominal aortic calcification has been found to be a valid
surrogate for assessing CAC (area under the curve 0.78)
[28, 31]. Each patient had one radiograph performed
shortly after his or her enrolment. A radiologist who was
blinded to each patient’s status interpreted all radiographs.
A second independent, blinded radiologist interpreted the
abdominal radiographs to confirm the findings of the first
radiologist (ICC = 0.99 (95% confidence interval 0.98–
0.99)). The ICC was calculated using a two-way mixed ef-
fects model with an absolute agreement definition.
Statistical analysis
Data were summarized as the mean +/− standard deviation
or median (interquartile range (IQR)). Univariate linear re-
gression was performed to determine the association of
serum Mg and pre-specified variables of interest with the
AAC score. Based on known risk factors for vascular calci-
fication, the following variables were examined in univariate
analysis: age (per year), sex, iPTH, serum Ca, serum PO4,
calculated LDL cholesterol, total time on dialysis (years),
smoking history (ex or current smoker vs non-smoker),
diabetes, serum albumin, and RRF. All variables with
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a p-value ≤0.2 on univariate regression were adjusted
for in the multiple linear regression model. We also
performed a multiple linear regression analysis where
all pre-specified variables were maintained in the
model. Five patients had missing LDL cholesterol
values (n = 1, no test was performed; n = 4, triglycer-
ides were too high to calculate LDL). Multiple imput-
ation (SPSS automatic imputation method) was used to
impute missing values for LDL in the multiple linear re-
gression analysis. SPSS automatically chooses an imput-
ation method that is most appropriate for the data and
uses linear regression to impute missing continuous vari-
ables. Five imputed datasets were created and the esti-
mates from each dataset were pooled.
We performed a sensitivity analysis where patients with
an aortic calcification score of 0 were removed from the
analysis. Patients with very little or no vascular calcifica-
tion do not tend to develop vascular calcification over
time and seem to represent a different subgroup from the
general end stage renal disease population [33, 34]. For
this reason, we performed a separate analysis to determine
the impact upon the overall results. All analyses were per-
formed using SPSS Statistics version 24. The reporting of




Eighty six patients provided informed consent; 80 patients
completed a lateral lumbar X-ray and were included in the
primary analysis. Patient selection is outlined in Fig. 1.
The baseline characteristics of included patients are
outlined in Table 1. The mean age of patients was
62.8 years, 56 patients (70%) were male, 34% were diabetic
and 33% were lifelong non-smokers. Mean serum Mg was
0.84 mmol/L (normal range 0.74 to 1.03 mmol/L) and
mean AAC score 8.9 (minimum score 0, maximum score
24). The mean serum PO4 level was 1.70 mmol/L and
mean LDL cholesterol 2.02 mmol/L. The median time on
dialysis was 1.3 years (IQR 0.6 to 3.0). Twenty six patients
(32.5%) had a low serum Mg (defined by <0.74 mmol/L),
42 patients (52.5%) had a normal serum Mg and 12 pa-
tients (15.0%) had a high serum Mg (defined as
>1.03 mmol/L). Most patients (77.5%) were on ambulatory
peritoneal dialysis (APD). Included patients used the
following PD fluid combinations: 1. Dianeal only in 19
(23.8%) patients, 2. Extraneal only in 4 (5.0%) patients, 3.
Dianeal and Extraneal in 54 (67.5%) patients, 4. Physioneal
and Extraneal in 3 (3.8%) patients.
Univariate regression
On univariate regression, age, serum phosphate, serum
iPTH, LDL cholesterol, smoking history, diabetes, and
Fig. 1 Patient selection. *These patients consented to participate
but then failed to complete the required lumbar x-ray despite
multiple reminders
Table 1 Baseline characteristics
Total N = 80
Age 62.8 (12.8)
Sex (male) 56 (70.0)
BMI (kg/metre squared) 28.33 (5.6)a
iPTH (pmol/L) 34.0 (28.6)
Serum Calcium (mmol/L) 2.3 (0.2)
Serum Phosphate (mmol/L) 1.7 (0.4)
LDL cholesterol (mmol/L) 2.0 (0.8)b
Time on dialysis (years) 1.3 (0.6, 3.0)c
Lifelong non-smoker 26 (32.5)
Diabetes 27 (33.8)
Serum Mg (mmol/L) 0.84 (0.2)
Number of patients with low serum Mg 26 (32.5)
Serum Albumin (g/L) 32.4 (4.5)
nPCR (g/kg/day) 0.8 (0.2)
RRF (mL/min) 4.7 (3.8)
Number of patients on a cholesterol lowering medication
(statin or ezetemibe)
55 (68.8)
Number of patients on APD 62 (77.5)
Aortic calcification score 8.9 (6.9)
Continuous measurements presented as mean (standard deviation (SD)), other
variables presented as N (%) unless otherwise specified
BMI body mass index, iPTH parathyroid hormone, LDL low density lipoprotein,
Mg magnesium, nPCR normalized catabolic rate, RRF Residual renal function,
APD automated peritoneal dialysis (the remainder of patients were on
continuous ambulatory peritoneal dialysis)
aMean value for 79 patients (1 patient had a missing value)
bMean value for 75 patients (5 patients had values that were missing or could
not be calculated)
cMedian, interquartile range (IQR)
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serum Mg had a p value ≤0.2. Older age, a higher serum
PO4, a lower serum Mg and a history of diabetes were
significantly associated with an increased AAC score
(p < 0.05). Higher LDL cholesterol was associated with
a decreased AAC score (p = 0.03) (Table 2).
Multiple linear regression
After adjustment for age, serum phosphate, serum iPTH,
LDL cholesterol, smoking history, and diabetes, a lower
serum Mg level was independently associated with a higher
AAC score (Unstandardized coefficient [B] = −10.98,
p = 0.000). This statistic translates to a 0.1 mmol/L
increase in serum Mg being associated with a 1.1-point
decrease in AAC score. When all pre-specified variables
(Table 2) were maintained in the model regardless of the
univariate analysis p value, the results were similar (B for
Mg = −11.50, p = 0.000). When patients with an AAC
score of 0 were excluded, n = 68 patients included in
the analysis, the results were similar (B for Mg = −12.27,
p = 0.001) (Table 3). Testing assumptions of the linear
regression model can be found in Additional file 1.
Discussion
Our data demonstrate that in PD patients, a lower serum
Mg is independently associated with an increased AAC
score. We found that a 0.1 mmol/L increase in serum Mg
is associated with a 1.1-point decrease in AAC score. This
suggests that Mg may act as a possible inhibitor of vascu-
lar calcification.
Our study results are consistent with previously pub-
lished observational and pilot studies in the dialysis and
chronic kidney disease populations [9, 13–19]. A recent co-
hort study with a maximum follow up of 10.8 years found
that a lower serum Mg was associated with increased mor-
tality in PD patients [23]. Several other studies have demon-
strated an association between lower serum Mg and
mortality among dialysis patients [21, 22, 24–27] This asso-
ciation could potentially be attributable to low serum Mg
causing accelerated vascular calcification. Increasing data
from in-vitro and animal studies support the assertion that
Mg acts as an inhibitor of vascular calcification [6–12]. The
addition of Mg to vascular smooth muscle cells increases
the expression of anti-calcification proteins, such as matrix
G1a, bone morphogenetic protein-7 and osteopontin, and
Table 2 Univariate linear regression
Variable R2 Unstandardized coefficient (B) 95% confidence interval (CI) P value
Age 0.17 0.22 0.11, 0.33 0.00
Sex 0.005 −1.04 −4.41, 2.33 0.54
iPTH 0.02 0.03 −0.02, 0.09 0.23
Calcium 0.00 0.04 −8.55, 8.63 0.99
Phosphate 0.07 4.52 0.91, 8.13 0.02
LDLa 0.07 −2.19 −4.09, −0.29 0.03
Time on dialysis 0.02 −0.40 −1.10, 0.30 0.26
Smoking history 0.03 2.53 −0.73, 5.79 0.13
Diabetes 0.06 3.51 0.33, 6.68 0.03
Albumin 0.004 −0.10 −0.45, 0.24 0.56
RRF 0.001 −0.05 −0.46, 0.37 0.83
Magnesium 0.06 −7.81 −15.01, −0.61 0.03
Smoking history (ex or current vs non-smoker)
iPTH intact parathyroid hormone
LDL low-density lipoprotein
RRF Residual renal function
a75 patients included in the analysis for LDL (5 patients had values that were missing or could not be calculated). 80 patients included for all other variables
Table 3 Multiple linear regression: the independent association of serum Mg with vascular calcification
Model Adjusted R2 of the model Unstandardized coefficient (B) for Mg 95% CI P value
1 0.34 −10.98 −17.40, −4.56 0.000
2 0.35 −11.50 −17.93, −5.06 0.000
3 0.18 −12.27 −19.54, −5.00 0.001
Model 1: Adjusted for age, serum phosphate, LDL cholesterol, iPTH, smoking history, and diabetes
Model 2: All pre-specified variables in Table 2 were included in the model
Model 3: Adjusted for the variables in model 1; patients with an aortic calcification score of 0 (N = 12) excluded from the analysis
Abbreviations: LDL low density lipoprotein cholesterol, iPTH intact parathyroid hormone
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inhibits an osteoblastic transformation [7, 11]. As well, the
addition of Mg to vascular smooth muscle cells down-
regulates the Wnt/β-catenin pathway. This pathway is es-
sential for the osteogenic transformation of pluripotent
mesenchymal cells and is activated during the development
of vascular calcification [11]. The mechanism by which Mg
regulates vascular calcification may involve the transient re-
ceptor potential melastin (TRPM)7 cation channel as inhib-
ition of TRPM7 negates the anti-calcification effects of Mg
[7, 11]. Mg may also inhibit vascular calcification by sup-
pressing PTH, which has been found in animal models to
increase vascular calcification [36, 37]. Among PD patients,
an inverse correlation between PTH and serum Mg, inde-
pendent of Ca concentration, has been demonstrated in
several studies [38–41]. However, in our cohort of PD pa-
tients, we did not find a significant, independent association
between serum Mg and PTH (data not shown). To our
knowledge, our study is the largest thus far in the PD popu-
lation (previously published PD study n = 44; outcome of
peripheral arterial calcification [16]), and the largest study
with a vascular calcification outcome that is a validated sur-
rogate for CAC.
AAC is a valid surrogate marker as it correlates with
CAC and is associated with increased all-cause and cardio-
vascular mortality [28, 42, 43]. Among diabetic patients, re-
ported hazard ratios for all-cause and cardiovascular
mortality were 1.7 and 1.9 respectively when the AAC score
was examined as a continuous variable [42]. Cardiovascular
mortality has also been found to increase in a graded fash-
ion with increasing tertile of AAC score [43].
Our study population had a mean serum Mg of
0.84 mmol/L, and over 32% of our cohort had low serum
Mg (defined as <0.74 mmol/L). The mean serum Mg was
similar in a study by Fein et al. (0.8 mmol/L) examining the
association of serum Mg with mortality in PD patients [23].
Comparatively, studies examining serum Mg in an HD
population found a higher mean Mg level of 1.14 mmol/L
[24], 0.92 mmol/L [26], and 0.86 mmol/L [21]. The high
prevalence of hypomagnesemia in our cohort of PD pa-
tients could be due to the continuous nature of PD,
coupled with the low magnesium concentration of com-
monly used PD solutions (Mg concentration ranging
from 0.25 to 0.75 mmol/L). Patients on automated PD
overnight using a PD solution containing 0.25 mmol/L
of Mg along with a day time dwell of an icodextrin so-
lution, (the most commonly used regimen at our insti-
tution), have an overall transperitoneal Mg loss of
3.26 mmol per 24 h [29]. Magnesium losses in the di-
alysate are compounded by the significant restrictions
of a renal diet. Taken together, this highlights the
unique risk of hypomagnesermia in PD patients, mak-
ing them an ideal population for testing interventions
targeted at increasing serum Mg and examining the ef-
fect on vascular calcification.
Our study has some important limitations. Due to the
cross-sectional nature of the study, we can only determine
association and not causation. Residual confounding is pos-
sible. However, we were able to adjust for important con-
founders associated with vascular calcification, such as
serum PO4 and age [3], and our findings were consistent
across unadjusted, adjusted and sensitivity analyses. A low
serum Mg may be a marker of generalized malnutrition
[44, 45] and inflammation, which are both associated with
increased vascular calcification [46, 47]. We did not directly
measure any inflammatory markers; however, albumin is a
recognized surrogate for inflammation and malnutrition.
On univariate analysis, albumin was not associated with the
AAC score, and the results of the multivariate analysis were
not attenuated upon adjustment for albumin. We only
measured serum Mg at one time point; it is possible that a
single measurement may not be reflective of an individual’s
overall Mg status. The imaging technique used in our study
did not allow us to reliably differentiate between medial
(AIM) and intimal calcification (AIC). Both types of
vascular calcification occur commonly in dialysis pa-
tients, often co-existing in the same patient, and are as-
sociated with increased mortality. However, among
dialysis patients, AIC has been found to be associated
with worse survival when compared to AIM. As well,
the clinical consequences of AIC and AIM differ. While
AIC represents advanced atherosclerosis that is associ-
ated with the development of plaques and occlusive dis-
ease, AIM causes arterial stiffness, increased pulse
pressure and left ventricular hypertrophy [4, 48, 49].
Conclusions
In conclusion, our results support the assertion that
Mg may inhibit vascular calcification, a condition that
is highly prevalent in the dialysis population and is
associated with increased mortality [2–4]. If our re-
sults can be duplicated in large observational studies
with repeated serum Mg and vascular calcification
measurements, interventions, such as Mg supplemen-
tation in hypomagnesemic patients, the use of Mg
based phosphate binders, or the use of PD solutions
with a higher Mg concentration and their effect on
vascular calcification warrant testing in the PD popu-
lation. Such interventions would be easy to administer
and would carry minimal side effects.
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